Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Combined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases
Korsana's lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease
Concurrent private financing of approximately $380 million expected to fund Korsana's operations into 2029, including multiple clinical trial data readouts expected in 2027
Conference call scheduled for April 1, 2026, at 8:00 am ET
Cyclerion Therapeutics, Inc. ("Cyclerion") (NASDAQ:CYCN) and Korsana Biosciences, Inc. ("Korsana"), a privately-held biotechnology company discovering and developin
